230 related articles for article (PubMed ID: 11465919)
1. Slowing down ALS--is this good or bad?
Munsat TL
Amyotroph Lateral Scler Other Motor Neuron Disord; 2001 Mar; 2 Suppl 1():S19-22. PubMed ID: 11465919
[TBL] [Abstract][Full Text] [Related]
2. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
Miller RG; Mitchell JD; Lyon M; Moore DH
Amyotroph Lateral Scler Other Motor Neuron Disord; 2003 Sep; 4(3):191-206. PubMed ID: 13129806
[TBL] [Abstract][Full Text] [Related]
3. Cost effectiveness: summary.
Ringel SP
Amyotroph Lateral Scler Other Motor Neuron Disord; 2002; 3 Suppl 1():S67-9. PubMed ID: 12396813
[No Abstract] [Full Text] [Related]
4. [Riluzole as a treatment for amyotrophic lateral sclerosis].
Borrás-Blasco J; Plaza-Macías I; Navarro-Ruiz A; Perís-Martí J; Antón-Cano A
Rev Neurol; 1998 Dec; 27(160):1021-7. PubMed ID: 9951030
[TBL] [Abstract][Full Text] [Related]
5. What has changed with riluzole?
Meininger V; Lacomblez L; Salachas F
J Neurol; 2000 Dec; 247 Suppl 6():VI/19-22. PubMed ID: 19714404
[TBL] [Abstract][Full Text] [Related]
6. What has changed with riluzole?
Meininger V; Lacomblez L; Salachas F
J Neurol; 2000 Dec; 247():19-22. PubMed ID: 11200701
[TBL] [Abstract][Full Text] [Related]
7. Measures of quality of life: pro.
Ludolph AC
Amyotroph Lateral Scler Other Motor Neuron Disord; 2002; 3 Suppl 1():S19. PubMed ID: 12396796
[No Abstract] [Full Text] [Related]
8. Factors influencing a patient's decision regarding riluzole: an early experience.
Rudnicki SA
J Neurol Sci; 1997 Oct; 152 Suppl 1():S80-1. PubMed ID: 9419060
[TBL] [Abstract][Full Text] [Related]
9. [Therapeutic concepts in Amyotrophic Lateral Sclerosis (ALS)].
Ludolph AC
Drug Res (Stuttg); 2013 Nov; 63 Suppl 1():S21. PubMed ID: 24242034
[No Abstract] [Full Text] [Related]
10. Drug therapy for amyotrophic lateral sclerosis: Where are we now?
Carter GT; Krivickas LS; Weydt P; Weiss MD; Miller RG
IDrugs; 2003 Feb; 6(2):147-53. PubMed ID: 12789618
[TBL] [Abstract][Full Text] [Related]
11. [Tolerance of riluzole in a phase IIIb clinical trial].
Lacomblez L; Dib M; Doppler V; Faudet A; Robin V; Salachas F; Bensimon G; Meininger V
Therapie; 2002; 57(1):65-71. PubMed ID: 12090150
[TBL] [Abstract][Full Text] [Related]
12. Plasma glutamate and glycine levels in patients with amyotrophic lateral sclerosis: the effect of riluzole treatment.
Andreadou E; Kapaki E; Kokotis P; Paraskevas GP; Katsaros N; Libitaki G; Zis V; Sfagos C; Vassilopoulos D
Clin Neurol Neurosurg; 2008 Mar; 110(3):222-6. PubMed ID: 18055102
[TBL] [Abstract][Full Text] [Related]
13. Do the benefits of currently available treatments justify early diagnosis and announcement? Arguments for.
Cashman NR
Neurology; 1999; 53(8 Suppl 5):S50-2; discussion S55-7. PubMed ID: 10560639
[TBL] [Abstract][Full Text] [Related]
14. [What are the etiological medical therapies in amyotrophic lateral sclerosis?].
Dib M
Rev Neurol (Paris); 2006 Jun; 162 Spec No 2():4S215-4S219. PubMed ID: 17128114
[TBL] [Abstract][Full Text] [Related]
15. A Cost-Effectiveness Framework for Amyotrophic Lateral Sclerosis, Applied to Riluzole.
Thakore NJ; Pioro EP; Udeh BL; Lapin BR; Katzan IL
Value Health; 2020 Dec; 23(12):1543-1551. PubMed ID: 33248509
[TBL] [Abstract][Full Text] [Related]
16. Vitamin E intake and quality of life in amyotrophic lateral sclerosis patients: a follow-up case series study.
Galbussera A; Tremolizzo L; Brighina L; Testa D; Lovati R; Ferrarese C; Cavaletti G; Filippini G
Neurol Sci; 2006 Jul; 27(3):190-3. PubMed ID: 16897634
[TBL] [Abstract][Full Text] [Related]
17. Toward more efficient clinical trials for amyotrophic lateral sclerosis.
Cudkowicz ME; Katz J; Moore DH; O'Neill G; Glass JD; Mitsumoto H; Appel S; Ravina B; Kieburtz K; Shoulson I; Kaufmann P; Khan J; Simpson E; Shefner J; Levin B; Cwik V; Schoenfeld D; Aggarwal S; McDermott MP; Miller RG
Amyotroph Lateral Scler; 2010 May; 11(3):259-65. PubMed ID: 19961263
[TBL] [Abstract][Full Text] [Related]
18. The use of herbal supplements and alternative therapies by patients with amyotrophic lateral sclerosis (ALS).
Vardeny O; Bromberg MB
J Herb Pharmacother; 2005; 5(3):23-31. PubMed ID: 16520295
[TBL] [Abstract][Full Text] [Related]
19. [Neuroprotective therapy for amyotrophic lateral sclerosis (ALS)].
Yanagisawa N; Shindo M
Rinsho Shinkeigaku; 1996 Dec; 36(12):1329-30. PubMed ID: 9128396
[TBL] [Abstract][Full Text] [Related]
20. [Etiological drug therapy for amyotrophic lateral sclerosis].
Cintas P
Rev Neurol (Paris); 2006 Jun; 162 Spec No 2():4S220-4S227. PubMed ID: 17128115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
